BioLife Solutions Files 8-K
Ticker: BLFS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 834365
| Field | Detail |
|---|---|
| Company | Biolife Solutions Inc (BLFS) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, exhibits
TL;DR
BioLife Solutions filed an 8-K on Jan 13, 2025, with financial statements and exhibits.
AI Summary
BioLife Solutions, Inc. filed a Form 8-K on January 13, 2025, reporting financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Bothell, WA, operates in the electromedical and electrotherapeutic apparatus industry.
Why It Matters
This filing indicates a routine update for BioLife Solutions, Inc., providing necessary financial and exhibit information to the SEC.
Risk Assessment
Risk Level: low — This is a standard SEC filing for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Numbers
- 001-36362 — SEC File Number (Identifies the company's filing with the SEC.)
- 94-3076866 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioLife Solutions, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Principal executive offices
- January 13, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report financial statements and exhibits as of January 13, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 13, 2025.
In which state is BioLife Solutions, Inc. incorporated?
BioLife Solutions, Inc. is incorporated in Delaware.
What is the address of BioLife Solutions, Inc.'s principal executive offices?
The address of BioLife Solutions, Inc.'s principal executive offices is 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021.
What is the Standard Industrial Classification code for BioLife Solutions, Inc.?
The Standard Industrial Classification code for BioLife Solutions, Inc. is 3845, which corresponds to Electromedical & Electrotherapeutic Apparatus.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 08:40:41
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BLFS The NASDAQ Stock Market
Filing Documents
- blfs-20250113.htm (8-K) — 25KB
- a991-q42024preliminaryreve.htm (EX-99.1) — 38KB
- imagea.jpg (GRAPHIC) — 77KB
- 0001628280-25-001252.txt ( ) — 295KB
- blfs-20250113.xsd (EX-101.SCH) — 2KB
- blfs-20250113_lab.xml (EX-101.LAB) — 21KB
- blfs-20250113_pre.xml (EX-101.PRE) — 12KB
- blfs-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, the BioLife Solutions, Inc. (the "Company") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of BioLife Solutions, Inc., dated January 13 , 202 5 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioLife Solutions, Inc. Date: January 13, 2025 By: /s/ Troy Wichterman Name: Troy Wichterman Title: Chief Financial Officer